The Filing Desk

Adaptive Biotechnologies vs Vericel

Adaptive Biotechnologies ADPT · Vericel VCEL · Biotechnology

Adaptive Biotechnologies reported revenue of $277 million in fiscal 2025, about the same as Vericel's $276 million in fiscal 2025. Adaptive Biotechnologies' revenue grew 54.8% in its latest year, and Vericel's grew 16.4%. Adaptive Biotechnologies had an operating margin of -20.6%, against 4.0% at Vericel. Free cash flow was −$49 million at Adaptive Biotechnologies and $25 million at Vericel.

Side by side

Adaptive BiotechnologiesVericel
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$277M$276M
Revenue growth54.8%16.4%
Revenue growth a year, last 5 years23.0%17.3%
Gross margin74.2%74.4%
Operating margin−20.6%4.0%
Net margin−21.5%6.0%
Free cash flow−$49M$25M
Free cash flow margin−17.7%9.0%
Return on capital−37.2%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.1%0.9%
Last close$29.04$56.96
P/E at the last close—89.0×
Insider trades, last 12 monthssold $121.6 millionsold $13.0 million
Piotroski F-score5 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Adaptive BiotechnologiesVericel
Operating margin
Percent of revenue
Adaptive BiotechnologiesVericel
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Adaptive BiotechnologiesVericel

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Adaptive Biotechnologies and Vericel pages.